CELYAD
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
CELYAD
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2007-01-01
Address:
Mont-saint-guibert, Brabant Wallon, Belgium
Country:
Belgium
Website Url:
http://www.celyad.com
Total Employee:
51+
Status:
Active
Contact:
+32(0) 10 39 41 00
Email Addresses:
[email protected]
Total Funding:
146.1 M USD
Technology used in webpage:
Person Schema Gravatar Profiles Lorem Ipsum Comcast 3 To 9 CcTLD Redirects
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Summit Therapeutics
Summit Therapeutics is a clinical-stage drug discovery and development company.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-06-30 | Biological Manufacturing Services | Biological Manufacturing Services acquired by Celyad | N/A |
| 2015-01-06 | OnCyte | OnCyte acquired by Celyad | N/A |
| 2014-11-05 | CorQuest Medical | CorQuest Medical acquired by Celyad | N/A |
Investors List
Fortress Investment Group
Fortress Investment Group investment in Post-IPO Equity - Celyad
Hunza Ventures
Hunza Ventures investment in Venture Round - Celyad
Grifols
Grifols investment in Venture Round - Celyad
Life Sciences Research Partners V.Z.W.
Life Sciences Research Partners V.Z.W. investment in Series B - Celyad
Hunza Ventures
Hunza Ventures investment in Series B - Celyad
Grifols
Grifols investment in Series B - Celyad
S.R.I.W.
S.R.I.W. investment in Series A - Celyad
Official Site Inspections
http://www.celyad.com Semrush global rank: 3.57 M Semrush visits lastest month: 4.05 K
- Host name: 109.230.214.35.bc.googleusercontent.com
- IP address: 35.214.230.109
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Celyad"
Celyad - Crunchbase Company Profile & Funding
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno …See details»
About Us - Celyad
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its …See details»
Celyad Company Profile | Management and Employees List
Celyad Profile and History. Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in …See details»
Celyad SA - AnnualReports.com
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company …See details»
Celyad Oncology - LinkedIn
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells.See details»
Celyad - Funding, Financials, Valuation & Investors - Crunchbase
Celyad has acquired 3 organizations. Their most recent acquisition was Biological Manufacturing Services on Jun 30, 2016 . Which types of acquisition does this organization make most …See details»
Celyad Inc. Company Profile | Boston, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Celyad Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Celyad Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Celyad has 5 employees across 2 locations and €102 k in annual revenue in FY 2023. See insights on Celyad including office locations, competitors, revenue, financials, …See details»
Celyad - Contacts, Employees, Board Members, Advisors & Alumni …
Celyad is a provider of cell therapy treatments with an initial focus on cardiology and oncology.See details»
Celyad - Overview, News & Similar companies | ZoomInfo.com
Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T candidate, which is currently being evaluated in a Phase 1 trial …See details»
2021 ANNUAL REPORT - Celyad
Including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of …See details»
Celyad - Directors - The Org
The Directors at Celyad are responsible for providing strategic oversight and governance to ensure the company effectively develops its stem cell-based therapies for cardiovascular …See details»
Celyad - Company Profile - Tracxn
Oct 22, 2024 Celyad ranks 505th among 2490 active competitors. 894 of its competitors are funded while 574 have exited. Overall, Celyad and its competitors have raised over $87.2B in …See details»
Newsroom - Celyad
Celyad Oncology reports first half year 2024 financial results and recent business highlights. Download PDF. 05. Apr 2024. Letter to Shareholders, non-regulated information, Press …See details»
Celyad Oncology provides an update on its strategic business …
Dec 21, 2022 Celyad Oncology is of the opinion that it will potentially create more shareholder value by licensing its patent estate and further strengthening its research efforts to improve the …See details»
Annual Report 2020 - celyad.com
Response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and …See details»
Celyad Oncology Reports Full Year 2023 Financial Results and …
Apr 4, 2024 Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), today announces its financial results for the fiscal year 2023 ended December …See details»
Celyad Oncology reports full year 2022 financial results and recent ...
Mar 23, 2023 and the early stage nature of the implementation of the Celyad 2.0 strategy, which involves shifting froman organization focused onclinical development to one prioritizing R&D …See details»
Celyad Oncology reports full year 2022 financial results and recent ...
Mar 23, 2023 This impairment comes as a result of the Company’s strategic shift in focus away from clinical development and the early stage nature of the implementation of the Celyad 2.0 …See details»